Back to Market返回行情
06
068270.KS Celltrion, Inc.
KSCHealthcare₩192,900+1.53%LatestMarket Cap: ₩42.13T
As of 2026-05-29 15:30
Valuation
P/E (TTM)
35.56
PEG
—
P/B
2.55
P/S
9.43
EV/EBITDA
22.08
DCF Value
—
FCF Yield
1.2%
Div Yield
0.4%
Margins & Returns
Gross Margin
59.9%
Operating Margin
29.9%
Net Margin
28.4%
ROE
7.4%
ROA
5.5%
ROIC
5.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | ₩1.14T | 57.9% | ₩321.87B | ₩346.14B | ₩1,582.19 | — |
| Q4 2025 | ₩1.33T | 63.4% | ₩470.64B | ₩527.93B | ₩2,296.05 | — |
| Q3 2025 | ₩1.03T | 60.8% | ₩301.41B | ₩331.35B | ₩1,508.00 | — |
| Q2 2025 | ₩961.46B | 56.6% | ₩242.47B | ₩61.17B | ₩276.00 | — |
| Q1 2025 | ₩841.91B | 52.6% | ₩149.42B | ₩108.67B | ₩508.65 | — |
| Q4 2024 | ₩1.06T | 51.1% | ₩196.40B | ₩236.65B | ₩1,090.13 | — |
| Q3 2024 | ₩881.93B | 52.5% | ₩207.69B | ₩85.59B | ₩379.12 | — |
| Q2 2024 | ₩874.74B | 42.0% | ₩72.49B | ₩78.01B | ₩345.00 | — |
| Q1 2024 | ₩736.98B | 31.7% | ₩15.44B | ₩22.44B | ₩99.18 | — |
| Q4 2023 | ₩382.60B | 35.4% | ₩18.40B | ₩1.05B | ₩7.26 | — |
| Q3 2023 | ₩672.29B | 55.1% | ₩267.63B | ₩221.83B | ₩1,570.60 | — |
| Q2 2023 | ₩523.98B | 52.7% | ₩182.99B | ₩147.51B | ₩1,034.63 | — |